Angle
Assaying both CTCs and ctDNA simultaneously offers a path to more accurate and early cancer detection and drug response monitoring.
In Brief This Week: Bionano Genomics, IntelliGenome, Pacific Biosciences, Revvity, Angle
News items for the week of Jan. 20, 2025.
Angle Acquires Option to License NuProbe Pan-Cancer NGS Panel
Angle said the panel would help advance its efforts to develop a liquid biopsy assay for circulating tumor cells and ctDNA.
In Brief This Week: Hologic, Illumina, LGC Biosearch, Agilent, Abbott, Eurofins, Centogene, More
News items for the week of Sept. 16, 2024.
Angle Raises $630K in Open Offer of Shares
The company said the proceeds will strengthen its balance sheet as it works to advance its circulating tumor cell platform for diagnostics and drug development.
Apr 24, 2024
Angle Inks Assay Development Deal with AstraZeneca
Oct 31, 2022
Sep 30, 2021
Angle H1 Revenues Up 26 Percent
Jun 25, 2021